Critical Review: VolitionRx (NYSE:VNRX) vs. Global WholeHealth Partners (OTCMKTS:GWHP)

VolitionRx (NYSE:VNRX) and Global WholeHealth Partners (OTCMKTS:GWHP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares VolitionRx and Global WholeHealth Partners’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VolitionRx	$770,000.00	76.96	-$35.32 million	($0.51)	-1.42
Global WholeHealth Partners	$10,000.00	0.00	-$5.16 million	N/A	N/A

Global WholeHealth Partners has lower revenue, but higher earnings than VolitionRx.

Volatility & Risk

VolitionRx has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Comparatively, Global WholeHealth Partners has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for VolitionRx and Global WholeHealth Partners, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VolitionRx	0	0	1	0	3.00
Global WholeHealth Partners	0	0	0	0	N/A

VolitionRx currently has a consensus price target of $2.50, indicating a potential upside of 246.21%.

Profitability

This table compares VolitionRx and Global WholeHealth Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VolitionRx	-4,557.29%	N/A	-154.24%
Global WholeHealth Partners	N/A	N/A	N/A

Institutional & Insider Ownership

8.1% of VolitionRx shares are owned by institutional investors. 15.4% of VolitionRx shares are owned by insiders. Comparatively, 10.3% of Global WholeHealth Partners shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

VolitionRx beats Global WholeHealth Partners on 5 of the 8 factors compared between the two stocks.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

About Global WholeHealth Partners

Global WholeHealth Partners Corporation develops and markets various in-vitro diagnostic (IVD) test kits in the United States. The company offers approximately 125 diagnostic tests kits for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, yellow fever, and other epidemic and vector-borne diseases. The company was incorporated in 2013 and is based in Newport Beach, California.